Norrett Kevin 4
4 · Sierra Oncology, Inc. · Filed Jul 1, 2022
Insider Transaction Report
Form 4
Norrett Kevin
Chief Business Officer
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2022-07-01−100,000→ 0 totalExercise: $12.05Exp: 2030-08-10→ Common Stock (100,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−49,000→ 0 totalExercise: $12.15Exp: 2030-08-12→ Common Stock (49,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−35,000→ 0 totalExercise: $31.54Exp: 2032-03-14→ Common Stock (35,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−11,700→ 0 totalExercise: $16.73Exp: 2031-03-15→ Common Stock (11,700 underlying)
Footnotes (5)
- [F1]The option vested as to 25% of the total shares on August 10, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F2]Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
- [F3]On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
- [F4]The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
- [F5]The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.